Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents
Journal of Fungi · 20.02.2026 · 12 (2) · 152
DOI: 10.3390/jof12020152 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Fungi, online erschienen am 20.02.2026. Verfasst von Guillermo Quindós und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Microbiology and Parasitology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48080 Bilbao, S…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejería de Educación, Universidades e Investigación of the Gobierno Vasco-Eusko Jaularitza.
Abstract (Originalsprache)
Vulvovaginal candidiasis (VVC) represents a widespread gynaecological challenge, affecting approximately 75% of women at some point during their reproductive years, with a significant subset progressing to recurrent forms (RVVC). Classical azoles and polyenes remain the cornerstone of therapy. However, their clinical utility is undermined by the rise of azole-resistant non-Candida albicans species, the capacity of Candida to form biofilms, and a complex variety of host-related factors that complicate disease expression and therapeutic response. This narrative review provides a critical up-to-date examination of the therapeutic landscape, integrating current diagnostic algorithms with pharmacological strategies for both acute, recalcitrant and recurrent VVCs. We assess the efficacy and safety of established antifungal agents alongside the breakthrough introduction of novel drug classes, with a particular interest in the oral triterpenoid ibrexafungerp and the tetrazole oteseconazole, which offer new mechanisms of action for cases that fail to respond to standard regimens. Furthermore, we address the management of a special clinical scenarios, including pregnancy and lactation, and explore promising emerging innovative approaches such as mucoadhesive formulations, immunomodulatory approaches, and alternative non-antifungal therapies. Ultimately, this review aims to support clinical decision-making by balancing the accessibility and user-friendliness of conventional treatments with the targeted precision offered by modern antifungal agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, Microbiology and Parasitology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48080 Bilbao, Spain.
- Instituto de Investigación Sanitaria Biobizkaia, 48903 Barakaldo, Spain.
- Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48080 Bilbao, Spain.
ORCID-Profile: Guillermo Quindós, Iker De-la-Pinta, Cristina Marcos-Arias, Nerea Jauregizar, Elena Sevillano, Elena Eraso
Förderung
- Consejería de Educación, Universidades e Investigación of the Gobierno Vasco-Eusko Jaularitza
Zitieren
APA
Quindós, G., De-la-Pinta, I., Marcos-Arias, C., Jauregizar, N., Sevillano, E., Madariaga, L., & Eraso, E. (2026). Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents. Journal of Fungi, 12(2), 152. https://doi.org/10.3390/jof12020152
Vancouver
Quindós G, De-la-Pinta I, Marcos-Arias C, Jauregizar N, Sevillano E, Madariaga L, et al. Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents. Journal of Fungi. 2026;12(2):152. doi:10.3390/jof12020152
BibTeX
@article{Quinds2026,
author = {Quindós, Guillermo and De-la-Pinta, Iker and Marcos-Arias, Cristina and Jauregizar, Nerea and Sevillano, Elena and Madariaga, Lucila and Eraso, Elena},
title = {Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents},
journal = {Journal of Fungi},
year = {2026},
volume = {12},
number = {2},
pages = {152},
doi = {10.3390/jof12020152}
}
EUVIMED